Imperial College London
We believe the care of depression should be personalised and measurement based
Currently, clinical assessment is based on questionnaires taken at infrequent time points or long neuropsychological testing which are subject to self report bias and limited sensitivity. Furthermore, the heterogeneity of depression obscures many study results as patients diagnosed with “major depression” may only share few symptoms and often report opposite symptoms. We are developing a technology that extracts digital biomarkers from voice recordings. This offers unique advantages including objectivity and the ability to sample data more continuously in a natural environment (i.e. outside of clinics). Our aim is to provide a personalized monitoring system that addresses the symptom heterogeneity by using the patients’ own data as the baseline and to allow a robust measurement based care approach using this monitoring system.
Affect.AI (formerly Mind analytics) is a group of three individuals with passion and experience in innovating healthcare. Our CEO Dr. Wun Wong is a former director of a research group developing machine learning services in the health insurance industry. Our CTO Woochan Hwang is a 5th year medical student at Imperial with a BSc in biomedical engineering and research in deep learning applications in medical imaging and biosignals. Our CMO Alice Tang is a junior doctor with a BSc in pharmacology and extensive research experience in neuropsychiatry.
Apply for Cohort Four
Focusing on novel solutions that address the Future of Pain our Challenge Accelerator Programme offers a salary replacement to take six-months (full-time) away from the lab to develop a medical technology into a business venture. The programme offers entrepreneurship masterclasses, specialist advice, access to co-working space and an allowance for travel and consumables (up to £45,000).Applications Closed